← All trials
NCT04455750
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- May 15, 2023
- Completion date
- Sep 30, 2026
- First posted
- Jul 2, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 1002
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- Baylor UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.